Hamdan Jaafar A, Youssef Kerolos N, Khan Aafreen, Abdalla Mohammed A, Zakhary Christine M, Rushdi Hiam, Khan Safeera
Medicine, American University of Antigua, St. John, ATG.
Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus. 2021 Jul 14;13(7):e16384. doi: 10.7759/cureus.16384. eCollection 2021 Jul.
Acute coronary syndrome (ACS), a subdivision of ischemic cardiac disease, is the sudden occlusion of coronary vessels that results in decreased blood supply to heart muscles and possible infarction. Though some of the etiologies are hypertension, hyperlipidemia, diabetes mellitus, and tobacco; certain types of chemotherapies play a major role. Percutaneous coronary intervention (PCI) has shown lifesaving results via drug-eluting stent (DES) deployment into occluded vessels. In this study, DES utilization among patients receiving chemotherapy will be assessed to observe if it provides any prevention against ACS. Articles were systematically screened in three databases such as PubMed, PubMed Central (PMC), and Medical Literature Analysis and Retrieval System Online (MEDLINE) using keywords and Medical Subject Heading (MeSH) terms for applicable articles. Additionally, a few relevant articles from the Cochrane Library, Molecular Diversity Preservation International (MDPI), and The New England Journal of Medicine were also used. Inclusion/exclusion criteria were applied post article screening via title and abstracts. Quality appraisal check was done using the Scale for the Assessment of Narrative Review Articles (SANRA) checklist, A Measurement Tool to Assess Systematic Reviews (AMSTAR) checklist, Cochrane bias assessment tool, and Joanna Briggs Institute (JBI) checklist. Ten related studies were strictly reviewed. DES did not appear to play a preventable role against ACS during chemotherapy as no study was found assessing DES prophylactically and its efficacy in cancer patients. Future clinical trials on DES prophylactic use might be beneficial to evaluate if ACS adversities of chemotherapy can be prevented. This review is of significant benefit as cardiovascular adversities would not impede chemotherapy efficacy as cardiac adversities would not be part of the equation.
急性冠状动脉综合征（ACS）是缺血性心脏病的一个分支，是冠状动脉突然闭塞，导致心肌供血减少并可能发生梗死。虽然其一些病因是高血压、高脂血症、糖尿病和吸烟，但某些类型的化疗起主要作用。经皮冠状动脉介入治疗（PCI）通过将药物洗脱支架（DES）植入闭塞血管已显示出挽救生命的效果。在本研究中，将评估接受化疗患者中DES的使用情况，以观察其是否能预防ACS。使用关键词和医学主题词（MeSH）术语在三个数据库（如PubMed、PubMed Central（PMC）和医学文献分析与检索系统在线（MEDLINE））中系统筛选适用文章。此外，还使用了来自Cochrane图书馆、分子多样性保护国际（MDPI）和《新英格兰医学杂志》的一些相关文章。通过标题和摘要筛选文章后应用纳入/排除标准。使用叙述性综述文章评估量表（SANRA）清单、系统评价评估测量工具（AMSTAR）清单、Cochrane偏倚评估工具和乔安娜·布里格斯研究所（JBI）清单进行质量评估检查。对十项相关研究进行了严格审查。由于未发现有研究对DES在癌症患者中的预防性使用及其疗效进行评估，DES在化疗期间似乎对ACS没有预防作用。未来关于DES预防性使用的临床试验可能有助于评估是否可以预防化疗引起的ACS不良事件。这项综述具有重要意义，因为心血管不良事件不会像心脏不良事件那样影响化疗疗效。
